Quantcast

Latest Corinne Goldsmith Dickinson Center for Multiple Sclerosis Stories

2010-09-14 12:43:05

Adding albuterol, a compound commonly used to treat asthma and other respiratory diseases, to an existing treatment for patients with multiple sclerosis appears to improve clinical outcomes, according to a report in the September issue of Archives of Neurology, one of the JAMA/Archives journals. Multiple sclerosis (MS) is a chronic inflammatory disease characterized by the degeneration of myelin, which coats nerve cells in the white matter of the central nervous system. Patients with the...

2010-06-02 07:00:00

EXTON, Pa., June 2 /PRNewswire/ -- BioTrends released the first wave of LaunchTrends®: New Products in Multiple Sclerosis (MS), a three wave syndicated report series designed to track the uptake of Novartis's Extavia and Acorda's Ampyra. In the current wave of research, which measures success at the one month post launch mark for Ampyra and six months post launch mark for Extavia, BioTrends surveyed 82 neurologists and conducted qualitative interviews with a subset of 20...

2010-04-26 07:00:00

EXTON, Pa., April 26 /PRNewswire/ -- BioTrends is pleased to announce the publication of a new syndicated report, TreatmentTrends: Multiple Sclerosis. This report covers the use of disease-modifying agents (DMAs) for the treatment of multiple sclerosis (MS), as well as attitudes and perceptions toward these products, advantages and disadvantages, ideal patient types, barriers to growth and expected future use. In addition, respondents were queried about their awareness of and interest in...

2010-04-19 08:00:00

WALTHAM, Mass., April 19 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that early lines of therapy for the treatment of multiple sclerosis are dominated by Teva's Copaxone and Biogen Idec's Avonex, an interferon-beta (IFN-beta) agent. According to surveyed neurologists, Copaxone's superior side-effect profile, particularly the lack of flu-like symptoms, is a key driver of its first-line...

2010-01-22 14:37:00

SILVER SPRING, Md., Jan. 22 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Ampyra (dalfampridine) extended release tablets to improve walking in patients with multiple sclerosis (MS). In clinical trials, patients treated with Ampyra had faster walking speeds than those treated with an inactive pill (placebo). This is the first drug approved for this use. (Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO) MS is a chronic, often disabling,...

2009-12-22 07:00:00

NEW YORK, Dec. 22 /PRNewswire/ -- 2009 saw exciting research progress, unprecedented opportunities on the horizon, and more scientists than ever working on resolving important questions. Despite the year's economic and financial challenges, the National Multiple Sclerosis Society continues to propel research forward to end MS. In 2009 the Society provided over $33.5 million to support 345 new and ongoing projects in its research portfolio, plus $1.5 million for Fast Forward, the Society's...

2009-07-27 16:00:00

INDIANAPOLIS and EDMONTON, Alberta, July 27 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) and BioMS Medical Corp. (TSX: MS) today announced that dirucotide did not meet the primary endpoint of delaying disease progression, as measured by the Expanded Disability Status Scale (EDSS), during the two-year MAESTRO-01 Phase III trial in patients with secondary progressive multiple sclerosis (SPMS). In addition, there were no statistically significant differences between dirucotide...

2009-04-29 12:47:00

Aurora St. Luke's Team Sees Lives Changed for the Better with Plasma Exchange. MILWAUKEE, April 29 /PRNewswire/ -- Researchers at Aurora St. Luke's Medical Center in Milwaukee report that plasma exchange therapy or PLEX dramatically improves the health of multiple sclerosis patients who fail to respond to conventional therapies. (Logo: http://www.newscom.com/cgi-bin/prnh/20090303/CG78204LOGO-b) "There is no other treatment that brings about such a reversal in multiple sclerosis," says...

2009-04-15 08:46:00

Only 39 Percent of Newly Diagnosed Patients Receive a Drug Within One Year of Their First Diagnosis, According to a New Report from Decision Resources WALTHAM, Mass., April 15 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that surveyed neurologists anticipate that less than 30 percent of their use of emerging oral agents --- Merck Serono's oral cladribine, Novartis/Mitsubishi Pharma's...

2009-02-18 14:46:00

Aurora St. Luke's Medical Center Discovers Way to Fight Rare, but Deadly, Side Effect from Drug. MILWAUKEE, Feb. 18 /PRNewswire/ -- Researchers at Aurora St. Luke's Medical Center have developed a technique that counteracts an unusual, but serious, side effect from natalizumab (Tysabri(R)), a drug that fights multiple sclerosis (MS). The side effect is a brain virus called progressive multifocal leukoencephalopathy (PML). "This virus looks like a multiple sclerosis relapse," Dr. Bhupendra...


Word of the Day
snash
  • To talk saucily.
  • Insolent, opprobrious language; impertinent abuse.
This word is Scots in origin and probably imitative.